40 related articles for article (PubMed ID: 9935023)
1. Association between apolipoprotein(a) polymorphism and Lp(a) levels in Koreans.
Hong SH; Min WK; Cheon SI; Lee CC; Song J; Kim JQ
Mol Cells; 1998 Oct; 8(5):544-9. PubMed ID: 9856341
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels.
Emdin CA; Khera AV; Natarajan P; Klarin D; Won HH; Peloso GM; Stitziel NO; Nomura A; Zekavat SM; Bick AG; Gupta N; Asselta R; Duga S; Merlini PA; Correa A; Kessler T; Wilson JG; Bown MJ; Hall AS; Braund PS; Samani NJ; Schunkert H; Marrugat J; Elosua R; McPherson R; Farrall M; Watkins H; Willer C; Abecasis GR; Felix JF; Vasan RS; Lander E; Rader DJ; Danesh J; Ardissino D; Gabriel S; Saleheen D; Kathiresan S; ;
J Am Coll Cardiol; 2016 Dec; 68(25):2761-2772. PubMed ID: 28007139
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a) and Low-Molecular-Weight Apo(a) Phenotype as Determinants of New Cardiovascular Events in Patients with Premature Coronary Heart Disease.
Afanasieva OI; Tyurina AV; Ezhov MV; Razova OA; Klesareva EA; Pokrovsky SN
Diseases; 2023 Oct; 11(4):. PubMed ID: 37873789
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Apolipoprotein(a) Isoform Size Using Phenotypic and Genotypic Methods.
Fogacci F; Di Micoli V; Avagimyan A; Giovannini M; Imbalzano E; Cicero AFG
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762189
[TBL] [Abstract][Full Text] [Related]
5. Malnutrition-inflammation-atherosclerosis syndrome in Chronic Kidney disease.
Rao P; Reddy GC; Kanagasabapathy AS
Indian J Clin Biochem; 2008 Jul; 23(3):209-17. PubMed ID: 23105756
[TBL] [Abstract][Full Text] [Related]
6. Coronary heart disease in young adults.
Rubin JB; Borden WB
Curr Atheroscler Rep; 2012 Apr; 14(2):140-9. PubMed ID: 22249950
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus.
Gazzaruso C; Coppola A; Montalcini T; Baffero E; Garzaniti A; Pelissero G; Collaviti S; Grugnetti A; Gallotti P; Pujia A; Solerte SB; Giustina A
Endocrine; 2012 Feb; 41(1):89-95. PubMed ID: 21986921
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a): an elusive cardiovascular risk factor.
Berglund L; Ramakrishnan R
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2219-26. PubMed ID: 15345512
[TBL] [Abstract][Full Text] [Related]
9. Premature coronary artery disease: clinical risk factors and prognosis.
Cole JH; Sperling LS
Curr Atheroscler Rep; 2004 Mar; 6(2):121-5. PubMed ID: 15023296
[TBL] [Abstract][Full Text] [Related]
10. Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects.
Emanuele E; Peros E; Minoretti P; Falcone C; D'Angelo A; Montagna L; Geroldi D
BMC Cardiovasc Disord; 2003 Dec; 3():12. PubMed ID: 14670093
[TBL] [Abstract][Full Text] [Related]
11. Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism.
Gazzaruso C; Garzaniti A; Giordanetti S; Falcone C; Fratino P
Cardiovasc Diabetol; 2002 Nov; 1():5. PubMed ID: 12473160
[TBL] [Abstract][Full Text] [Related]
12. Relation of Apo(a) size to carotid atherosclerosis in an elderly multiethnic population.
Paultre F; Tuck CH; Boden-Albala B; Kargman DE; Todd E; Jones J; Paik MC; Sacco RL; Berglund L
Arterioscler Thromb Vasc Biol; 2002 Jan; 22(1):141-6. PubMed ID: 11788474
[TBL] [Abstract][Full Text] [Related]
13. Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age.
Gazzaruso C; Garzaniti A; Buscaglia P; Bonetti G; Falcone C; Fratino P; Finardi G; Geroldi D
J Am Coll Cardiol; 1999 Jan; 33(1):157-63. PubMed ID: 9935023
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension.
Gazzaruso C; Buscaglia P; Garzaniti A; Bonetti G; Savino S; Mariotti S; Jucci A; Finardi G; Geroldi D
J Cardiovasc Risk; 1996 Apr; 3(2):191-7. PubMed ID: 8836862
[TBL] [Abstract][Full Text] [Related]
15. Genetics and cardiovascular risk: a role for apolipoprotein(a) polymorphism.
Gazzaruso C; Garzaniti A; Geroldi D; Finardi G
Cardiologia; 1999 Apr; 44(4):347-54. PubMed ID: 10371786
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease.
Peros E; Geroldi D; D'Angelo A; Falcone C; Montagna L; Carabela M; Emanuele E
Int J Mol Med; 2004 Feb; 13(2):243-7. PubMed ID: 14719130
[TBL] [Abstract][Full Text] [Related]
17. Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation.
Emanuele E; Peros E; Minoretti P; D'Angelo A; Montagna L; Falcone C; Geroldi D
Clin Chim Acta; 2004 Dec; 350(1-2):159-65. PubMed ID: 15530473
[TBL] [Abstract][Full Text] [Related]
18. Predictive genetic testing to control coronary heart disease and hyperlipidemia.
Berg K
Arteriosclerosis; 1989; 9(1 Suppl):I50-8. PubMed ID: 2521445
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
